- Home
- AKTX vs UBX Comparison
AKTX vs UBX Comparison
Compare AKTX & UBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKTX
- UBX
- Stock Information
- Founded
- AKTX N/A
- UBX 2009
- Country
- AKTX United States
- UBX United States
- Employees
- AKTX 12
- UBX N/A
- Industry
- AKTX Biotechnology: Pharmaceutical Preparations
- UBX Biotechnology: Pharmaceutical Preparations
- Sector
- AKTX Health Care
- UBX Health Care
- Exchange
- AKTX Nasdaq
- UBX Nasdaq
- Market Cap
- AKTX 25.7M
- UBX 36.9M
- IPO Year
- AKTX N/A
- UBX 2018
- Fundamental
- Price
- AKTX $0.97
- UBX $1.94
- Analyst Decision
- AKTX
- UBX Strong Buy
- Analyst Count
- AKTX 0
- UBX 2
- Target Price
- AKTX N/A
- UBX $7.00
- AVG Volume (30 Days)
- AKTX 30.9K
- UBX 203.3K
- Earning Date
- AKTX 03-04-2025
- UBX 04-14-2025
- Dividend Yield
- AKTX N/A
- UBX N/A
- EPS Growth
- AKTX N/A
- UBX N/A
- EPS
- AKTX N/A
- UBX N/A
- Revenue
- AKTX N/A
- UBX N/A
- Revenue This Year
- AKTX N/A
- UBX N/A
- Revenue Next Year
- AKTX N/A
- UBX $33.62
- P/E Ratio
- AKTX N/A
- UBX N/A
- Revenue Growth
- AKTX N/A
- UBX N/A
- 52 Week Low
- AKTX $0.90
- UBX $0.94
- 52 Week High
- AKTX $4.40
- UBX $3.10
- Technical
- Relative Strength Index (RSI)
- AKTX 39.06
- UBX 48.69
- Support Level
- AKTX $1.00
- UBX $1.99
- Resistance Level
- AKTX $1.08
- UBX $2.17
- Average True Range (ATR)
- AKTX 0.12
- UBX 0.22
- MACD
- AKTX -0.02
- UBX -0.05
- Stochastic Oscillator
- AKTX 5.00
- UBX 22.41
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing therapies for autoimmune and inflammatory diseases involving the complement component 5 (C5) and leukotriene B4 (LTB4) pathways. The company's pipelines include HSCT-TMA and Geographic Atrophy (GA).
About UBX Unity Biotechnology Inc.
Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases. Its drug candidates include, UBX1325 is being developed for age-related diseases of the eye, including diabetic macular edema, or DME, UBX2089, which is a circulating hormone primarily produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications, and UBX2050.